SPATA2 Antibody

What tissue expression patterns should researchers expect when studying SPATA2?

SPATA2 shows variable expression across different tissues. Studies in mice have demonstrated detectable expression in multiple tissues including brain, heart, and spleen, with notably higher expression in lungs, intestines, and testes . When designing experiments, researchers should account for this differential expression pattern. For example, when validating antibody specificity, testis tissue from mice or rats serves as an excellent positive control as both show strong SPATA2 expression . Understanding these expression patterns is crucial for experimental design, particularly when selecting appropriate control tissues or establishing baseline expression levels in comparative studies.

What applications are SPATA2 antibodies suitable for in research?

SPATA2 antibodies have been validated for multiple experimental applications including:

It is essential to note that optimal dilutions vary between applications and should be empirically determined for each experimental system . Positive Western blot detection has been specifically validated in mouse and rat testis tissue, while immunohistochemistry has been confirmed in mouse lung tissue using antigen retrieval with TE buffer (pH 9.0) or alternatively with citrate buffer (pH 6.0) .

What are the optimal storage conditions for maintaining SPATA2 antibody activity?

SPATA2 antibodies should be stored at -20°C for optimal preservation of activity . Most commercial preparations come in liquid form containing PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . For long-term storage at -20°C, aliquoting is generally unnecessary, which reduces the risk of contamination and freeze-thaw degradation. Some preparations, particularly smaller volumes (e.g., 20μl sizes), may contain 0.1% BSA as a stabilizer . When designing multi-stage experiments, consider these storage requirements to maintain consistent antibody performance throughout your research timeline. Always check the manufacturer's specific recommendations, as formulations may vary slightly between suppliers.

How should I optimize antigen retrieval for SPATA2 immunohistochemistry?

For effective immunohistochemical detection of SPATA2, antigen retrieval methodology is crucial. Based on validated protocols, the primary recommendation is to use TE buffer at pH 9.0 for antigen retrieval . As an alternative approach, citrate buffer at pH 6.0 has also been shown to work effectively . When establishing this technique in your laboratory, it is advisable to perform parallel experiments with both buffer systems to determine which provides optimal staining in your specific tissue samples. The choice between these methods may depend on tissue type, fixation conditions, and co-staining requirements. Additionally, include appropriate positive controls such as mouse lung tissue where SPATA2 expression has been confirmed through validated antibodies .

What controls should I include when studying SPATA2 knockout or knockdown models?

When investigating SPATA2 function through knockout or knockdown approaches, proper experimental controls are essential. Based on published research, genotyping of tail DNA and Western blotting should be employed to confirm knockout of SPATA2 expression . For cell culture models, the restoration of SPATA2 expression through complementation experiments provides a robust control for specificity. For example, studies have shown that the sensitivity to necroptosis can be restored upon complementation of SPATA2 in knockdown cells, confirming the specific role of SPATA2 in this process . When analyzing phenotypes, comparing wildtype, heterozygous, and homozygous knockout models can provide insights into gene dosage effects. Additionally, using RIPK1 inhibitors such as Nec-1s in parallel experiments can help distinguish which phenotypes are RIPK1-dependent versus independent .

How can I investigate SPATA2's role in TNF-induced cell death pathways?

To investigate SPATA2's role in TNF-induced cell death, multiple experimental approaches can be employed based on recent research findings. Researchers can induce necroptosis in cell models using TNFα combined with caspase inhibitors (such as zVAD.fmk or IDN-6556) and compare responses between wildtype and SPATA2-deficient cells . For analyzing RIPK1 activation, which is a key event in these pathways, utilize antibodies targeting phosphorylated RIPK1 at Serine 166 (p-S166 RIPK1), a biomarker for RIPK1 activation . This approach allows for immunoprecipitation of activated RIPK1 and subsequent analysis of complex IIb components.

The experimental design should include:

• Treatment conditions comparing TNFα alone versus TNFα plus caspase inhibitors

• Inclusion of specific inhibitors like Nec-1s (RIPK1 inhibitor)

• Time-course experiments to capture the dynamics of complex formation

• Analysis of downstream phosphorylation events, particularly MLKL phosphorylation

Studies have demonstrated that SPATA2-deficient cells show significantly reduced levels of activated RIPK1, suggesting that SPATA2 promotes the formation of complex IIb during necroptosis .

What experimental models can be used to study SPATA2's role in inflammatory responses?

To investigate SPATA2's function in inflammatory responses, several in vitro and in vivo models have been validated. In cellular systems, bone marrow-derived macrophages (BMDMs) and mouse embryonic fibroblasts (MEFs) from wild-type and SPATA2-deficient mice provide excellent comparative models . For in vivo studies, the systemic inflammatory response syndrome (SIRS) model induced by TNFα administration has revealed that SPATA2-deficient mice exhibit heightened sensitivity rather than protection .

Experimental approaches should include:

• Measurement of inflammatory cytokines (particularly IL-6, IL-10, and TNFα) in cell culture supernatants or mouse sera

• Analysis of MAPK pathway activation, especially JNK phosphorylation

• Assessment of caspase activation in relevant tissues (e.g., gut tissue after TNFα challenge)

• Combinatorial approaches using RIPK1 inhibitors to determine pathway dependency

Research has shown that SPATA2-deficient mice challenged with TNFα demonstrate higher levels of IL-6 and IL-10 in their sera, which can be reduced by RIPK1 kinase inhibitor Nec-1s . This model allows for the investigation of the "cytokine storm" phenomenon that plays a key role in the lethal effect of TNFα and LPS in vivo .

How does SPATA2 regulate ubiquitination dynamics in TNF signaling?

SPATA2 plays a critical role in modulating ubiquitination processes within the TNF signaling pathway. To study this function, researchers can design experiments investigating the interaction between SPATA2, CYLD, and the linear ubiquitin chain assembly complex (LUBAC) . SPATA2 deficiency has been shown to promote M1 ubiquitination of RIPK1, which inhibits RIPK1 kinase activity .

For investigating these ubiquitination dynamics, consider:

• Immunoprecipitation experiments to isolate RIPK1 and analyze its ubiquitination status

• In vitro deubiquitination assays with purified proteins to assess the preference of the USP domain of CYLD and the PUB domain of SPATA2 for M1 ubiquitin chains

• Reconstitution experiments in SPATA2-deficient cells with wild-type SPATA2 or mutants affecting specific domains

• Mass spectrometry analysis to identify the composition of protein complexes pulled down by antibodies against phosphorylated RIPK1

Biochemical evidence indicates that the USP domain of CYLD and the PUB domain of the SPATA2 complex preferentially deubiquitinate the M1 ubiquitin chain in vitro , providing a mechanistic explanation for how SPATA2 regulates RIPK1 activation.

What might cause variability in SPATA2 antibody detection across different experimental systems?

Several factors can contribute to variability in SPATA2 antibody detection. First, the observed molecular weight of SPATA2 (58-60 kDa) may sometimes differ slightly from the calculated weight (58 kDa) due to post-translational modifications . When troubleshooting detection issues, consider:

• Tissue-specific expression patterns: SPATA2 expression varies significantly across tissues, with highest levels in lungs, intestines, and testes

• Buffer compatibility: For Western blotting, ensure your extraction buffer preserves protein-protein interactions if studying SPATA2 complexes

• Antibody specificity: Different antibodies target different epitopes of SPATA2, some recognizing specific regions (e.g., AA 422-519 or AA 1-520)

• Cross-reactivity considerations: Verify antibody specificity through knockout controls or competitive binding assays

When inconsistent results occur, a systematic approach involving parallel testing of different antibody dilutions, antigen retrieval methods, and detection systems can help identify optimal conditions for your specific experimental system.

How can I validate SPATA2 antibody specificity in my experimental system?

Validating antibody specificity is crucial for reliable research outcomes. For SPATA2 antibodies, a multi-faceted validation approach is recommended:

• Positive control tissues: Use mouse or rat testis tissue for Western blotting, mouse lung tissue for IHC, and HeLa cells for immunofluorescence as these have been validated for SPATA2 detection

• Knockout/knockdown controls: Compare signal between wild-type and SPATA2-deficient samples; the absence of signal in knockout samples strongly supports antibody specificity

• Peptide competition assays: Pre-incubation of the antibody with its immunizing peptide should abolish specific staining

• Multiple antibody validation: Use antibodies raised against different epitopes of SPATA2 to confirm detection patterns

• Molecular weight verification: Confirm that the detected band appears at the expected molecular weight (58-60 kDa for SPATA2)

This comprehensive validation approach ensures that experimental findings truly reflect SPATA2 biology rather than potential cross-reactivity artifacts.

What are the critical steps for successful immunoprecipitation of SPATA2 complexes?

Immunoprecipitation of SPATA2 and its interaction partners requires careful attention to preserve protein-protein interactions. When designing such experiments:

• Buffer considerations: Use buffers that maintain native protein conformation and preserve weak interactions (often low-detergent formulations)

• Cross-linking options: Consider whether chemical cross-linking might be necessary to capture transient interactions

• Antibody selection: Choose antibodies validated for immunoprecipitation applications; not all SPATA2 antibodies are suitable for this purpose

• Sequential immunoprecipitation: For studying complex formation, sequential IP can help identify direct versus indirect interactions

• Mass spectrometry validation: Consider mass spectrometry analysis of immunoprecipitated complexes to confirm the presence of expected interaction partners

For specific applications focusing on activated RIPK1 complexes, antibodies against phosphorylated RIPK1 (p-S166) have been successfully used to isolate complex IIb components, including RIPK1, RIPK3, FADD, caspase-8, cFLIP, and TRADD .

How might SPATA2 antibodies be utilized in exploring novel disease associations?

SPATA2 was initially characterized in spermatogenesis but has subsequently been implicated in diverse pathological processes including psoriasis predisposition and TNF-induced cell death . This expanding functional profile suggests potential roles in multiple disease contexts that remain to be fully explored. Researchers can utilize SPATA2 antibodies to investigate:

• Autoimmune disorders: Given SPATA2's role in inflammatory signaling and cytokine production, examine its expression and activation in tissues from autoimmune disease models

• Pancreatic disorders: Explore SPATA2's reported role in pancreatic development and β-cell proliferation through immunohistochemical analysis of pancreatic tissue sections

• Neurodegenerative conditions: Investigate potential contributions to neuroinflammatory processes through co-localization studies with markers of microglial activation

• Cancer biology: Examine SPATA2 expression patterns in tumor tissues, particularly in contexts where TNF signaling and cell death resistance are relevant

By combining traditional antibody-based detection methods with emerging technologies such as single-cell analysis and spatial transcriptomics, researchers can uncover novel associations between SPATA2 expression patterns and disease phenotypes.

What experimental approaches could elucidate the regulatory mechanisms controlling SPATA2 expression?

While much research has focused on SPATA2's function, less is known about how SPATA2 expression itself is regulated. Researchers interested in this question could employ:

• Promoter analysis: Use reporter assays to identify transcription factors regulating SPATA2 expression

• Epigenetic profiling: Apply ChIP-seq and bisulfite sequencing to characterize chromatin modifications at the SPATA2 locus

• Tissue-specific expression mechanisms: Investigate why SPATA2 shows higher expression in lungs, intestines, and testes compared to other tissues

• Post-transcriptional regulation: Examine potential microRNA binding sites in SPATA2 mRNA and test their functional relevance

• Stress response induction: Determine whether inflammatory stimuli or cell stress conditions alter SPATA2 expression levels

These approaches would provide valuable insights into the molecular mechanisms controlling SPATA2 expression, potentially revealing new regulatory circuits that could be targeted for therapeutic intervention in conditions where SPATA2 dysregulation contributes to pathology.

How can SPATA2 antibodies be integrated into high-throughput screening approaches?

SPATA2 antibodies could be valuable tools in high-throughput screening (HTS) for compounds that modulate inflammatory and cell death pathways. Researchers developing such screening platforms might consider:

• Automated immunofluorescence assays: Develop cell-based assays measuring SPATA2 localization changes in response to compound treatment

• Phospho-RIPK1 detection: Create high-content screening assays using antibodies against phosphorylated RIPK1 to identify compounds that modulate RIPK1 activation downstream of SPATA2

• SPATA2-dependent cytokine production: Design assays measuring inflammatory cytokine secretion in wild-type versus SPATA2-deficient cells to identify pathway-specific modulators

• Protein-protein interaction disruption: Develop assays to identify compounds that interfere with SPATA2's interaction with CYLD or components of the LUBAC complex

Such screening approaches could identify novel compounds that modulate inflammatory signaling in a SPATA2-dependent manner, potentially leading to new therapeutic strategies for inflammatory disorders characterized by dysregulated TNF signaling.